Autres langues TaiMed Biologics Inc.

Actions

4147

TW0004147004

Cours en clôture Taipei Exchange Autres places de cotation 00:00:00 30/04/2024			Varia. 5j.	Varia. 1 janv.
85,5 ^TWD	-0,58 %		+4,52 %	+4,27 %

20/03	TaiMed Biologics Inc. annonce ses résultats pour l'exercice clos le 31 décembre 2023	CI
13/03	TaiMed Biologics et AcedrA Biopharmaceticals s'associent pour commercialiser le Trogarzo au Moyen-Orient et en Afrique du Nord	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

TaiMed Biologics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	20/03
Taimed Biologics and AcedrA Biopharmaceticals Partner to Commercialize Trogarzo in the Middle East and North Africa Region	13/03
Taimed Announces Its Marketing Partner Received Refusal to File Letter for Trogarzo Intramuscular Method of Administration sBLA from the US FDA	28/02
TaiMed Biologics Inc. Receives Patent Approval from the Taiwan Intellectual Property Office for Improving the Pharmacokinetic Performance of TMB-365 Using Histidine Modification Technology	21/02
TaiMed Biologics Inc. Announces US FDA Grants Fast Track Designation to TMB-365/TMB-380 Long-Acting Combination Therapy for HIV Infection	07/02
TaiMed Biologics Inc. Revises the Phase 2 Clinical Study Design of Bi-Monthly Dosing of TMB-365/TMB-380 Combination for the Treatment of HIV Infection	21/12
Taimed Biologics Inc. Announces US FAD Approves the sBLA for the IV Push Administration of the Loading Dose of Trogarzo	13/12
TaiMed Biologics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	14/11
Theratechnologies Reports Results from Trogarzo Intramuscular Administration Study; Tesamorelin Poster Presentation	13/10/23
TaiMed Biologics Inc. Announces Results from Trogarzo Intramuscular (IM) Administration Study	13/10/23
TaiMed Biologics Inc. Completes Data Analysis of the Clinical Trial Sentinel Group for the TMB-365 and TMB-380 Combination as Expected and Confirms the Dosing for Future Execution	06/09/23
TaiMed Biologics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	11/08/23
TaiMed Biologics Inc. Completes the Last Patient Visit of the Sentinel Group in the Clinical Study Evaluating Long-Acting TMB-365/TMB-380 Combination Maintenance Therapy	28/06/23
TaiMed Biologics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	12/05/23
TaiMed Biologics Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	10/03/23
TaiMed Biologics Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	10/03/23
TaiMed Biologics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	11/11/22
US FDA Approves the Supplemental Biologicslicense Application for Intravenous (IV) Pushadministration of Trogarzo	03/10/22
TaiMed Biologics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	15/08/22
TaiMed Biologics : First Patient Enrolled in the Study Evaluating Bi-monthly and Quarterly Dosing of the Long-Acting TMB-365/TMB-380 mAb Combination Maintenance Therapy	29/07/22

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues TaiMed Biologics Inc.

Actions

4147

TW0004147004

Autres langues

Filtres